Get to know our clinical trials
A clinical trial to evaluate the efficacy and safety of etentamig and daratumumab (etentamig) compared with daratumumab, lenalidomide, and dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are not eligible for transplantation.
THE OBJECTIVE OF THIS STUDY IS TO DETERMINE WHETHER ETENTAMIG IS SAFE AND TO IDENTIFY THE OPTIMAL DOSE OF ETENTAMIG WHEN COMBINED WITH DARATUMUMAB IN PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WHO ARE NOT ELIGIBLE FOR TRANSPLANTATION.
Technical Summary
- A PHASE II/III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETENTAMIG AND DARATUMUMAB (ETENTAMIG) COMPARED WITH DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE NOT ELIGIBLE FOR TRANSPLANTATION.
- Code EudraCT: 2025-520897-21
- Protocol number: M25-586
- Promoter: Abbvie
- Molecule/Drug: Daratumumab
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.